Overview
October 16-17: Conference
In a market that is constantly adapting and adjusting to the needs of the healthcare field, real-world evidence (RWE) is becoming increasingly important for regulatory and reimbursement decision-making. Historically used for post-market safety monitoring, RWE is now integrated throughout the product development lifecycle, and has led to the real-time analysis of data to better understand and gain insights on disease, approaches to treatment, and how to substantiate coverage decisions.
DIA’s Real-World Evidence Conference will explore new, innovative applications of RWE, and deliver cutting-edge insights to leverage this knowledge to advance healthcare decision-making.
While we develop our 2023 agenda, please take a moment to review the 2022 final agenda.
Participant Testimonials
“DIA RWE is the best RWE-related event I've attended - it has compelling speakers, strong education opportunities, and a great collective of attendees.” - Nicholaas Honig, JD, Associate Regulatory Counsel, Aetion
Need approval in order to attend? Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.
Today’s Baltimore is a place where good ideas and ambition are the currency that matter most. It’s a place where art is seen as a catalyst for conversation, food as a means of connection, and history as an opportunity for education. It’s an essential destination full of inclusive neighborhoods where all visitors will feel invited, welcomed, and seen. Click here to check out all the tour guides based on your interests.
Featured
Who should attend?
Join professionals from every corner of the vast realm of real-world data and real-world evidence:
- Academia
- Clinical Research
- Data analytics
- Epidemiology
- Health Economics and Outcomes Research
- Pharmacovigilance
- Policy
- Real-World Evidence
- Real-World Data
- Regulatory Science
- Technology development
Program Committee
-
David Martin, MD, MPH • Vice President, Global Head RWE, Medical Affairs
Moderna, United States -
John Concato, MD, MPH, MS • Associate Director for Real-World Evidence Analytics, OMP, CDER
FDA, United States -
Simon Dagenais, PhD, MSc • Senior Director, RWE Center of Excellence
Pfizer Inc, United States -
Rachele Hendricks-Sturrup, DrSc, MA, MSc • Research Director, Real-World Evidence
Duke-Robert J. Margolis, MD, Center for Health Policy, United States -
Brad Jordan, PhD • Senior Director, Head of Regulatory Affairs Policy
Flatiron Health, United States -
Nirosha M. Lederer, PhD, MS • Head, US Government Partnerships; Senior Director, RWE Strategy
Aetion, United States -
Charles Lee, MBA, MS • Executive Regulatory Science Director
AstraZeneca, United States -
Yun Lu, PhD, MS • Mathematical Statistician, Office of Biostatistics and Pharmacovigilance, CBER
FDA, United States -
Sarah Martin, PhD, MS • Senior Director, Science and Regulatory Advocacy
PhRMA, United States -
Brittany McKelvey • Director, Regualtory Affairs
Friends of Cancer Research, United States -
Keri Monda, PhD, MS • Executive Director, Center for Observational Research
Amgen, United States
